Mengcheng Shen, PhD

Clinical Expertise

Cardio-oncology

Research Interest

My research in cardo-oncology focuses on leveraging patient-derived induced pluripotent stem cells (iPSCs) to generate cardiovascular cells. I employ high-throughput CRISPR screens to identify off-target mechanisms that contribute to cardiovascular toxicity associated with anti-cancer drugs. My ultimate goals is to develop personalized cancer therapies that minimize off-target cardiovascular effects, ensuring safer and more effective treatment options for patients.

Education

• 2009: B.S., Nanjing Agricultural University, China
• 2012: M.Sc., Nanjing Agricultural University, China
• 2018: PhD, University of Alberta, Canada

Training

• 2018 - 2023: Postdoctoral Researcher, Stanford University, Stanford, CA
• 2023 - 2025: Instructor , Stanford University, Stanford, CA

Selected Research Publications